Clinical correlation between premature ovarian failure and a chromosomal anomaly in a 22-year-old Caucasian woman: a case report

Domenico Dell’Edera1*, Andrea Tinelli2, Oronzo Capozzi3, Annunziata Anna Epifania4, Antonio Malvasi5, Dominga Lofrese1, Elena Pacella6, Giusi Natalia Milazzo7, Eleonora Mazzone1, Manuela Leo1 and Mariano Rocchi3

Abstract

Introduction: Premature ovarian failure is defined as the cessation of ovarian activity before the age of 40 years. It is biochemically characterized by low levels of gonadal hormones (estrogens and inhibins) and high levels of gonadotropins (luteinizing hormone and follicle-stimulating hormone).

Case presentation: Our patient, a 22-year-old Caucasian woman under evaluation for infertility, had experienced secondary amenorrhea from the age of 18. No positive family history was noted regarding premature menopause. An examination of our patient’s karyotype showed the presence of a reciprocal translocation, apparently balanced, which had the X chromosome long arm (q13) and the 14 chromosome short arm (p12) with consequent karyotype: 46, X, t(X; 14)(q13;p12).

Conclusions: Our study has underlined that karyotyping is one of the fundamental investigations in the evaluation of amenorrhea. It highlighted a genetic etiology, in the form of a chromosomal abnormality, as the causal factor in amenorrhea.
Magnetic resonance imaging of her encephalon and hypophysis using paramagnetic contrast showed that her sellar cavity had regular morphology and dimensions, without any structural alterations. The adenohypophysis was devoid of alterations. Her hypophyseal peduncle oriented normally. Serum anti-ovarian and anti-adrenal antibodies were absent. As it is possible to see from the Table 1, our patient had high levels of gonadotropins (LH: 41.17IU/L and FSH: 79.90IU/L; hypergonadotropic amenorrhea) [2]. Her thyroid-stimulating hormone, free tri-iodothyronine and free thyroxin hormone levels were normal, while the levels of anti-thyroid peroxidase antibodies and anti-thyroglobulin antibodies were very high.

It was necessary, at this point, to conclude the diagnostics by studying her karyotype. Her karyotype was obtained from T lymphocytes extracted from peripheral blood using the common culture technique. The obtained chromosomes were banded with Q-banding methods using quinacrine. An examination of her karyotype revealed the presence of a mutual translocation, apparently balanced, that involved the X chromosome long arm (q13) and the 14 chromosome short arm (p12), with consequent karyotype 46,X,t(X;14)(q13;p12) (Figure 1).

Breakpoints were confirmed with fluorescent in situ hybridization (Figure 2, Table 2). To evaluate the inactivation of the X chromosome, we used the human androgen receptor (HUMARA) assay, which uses the locus of the androgen receptor in Xq11.2. In the first exon of the gene there was a highly polymorphic tri-nucleotide repetition (CAG) next to the cleavage sites of restriction enzymes sensitive to methylation (HpaII or HhaI), methylated only on the inactive X chromosome. The assay demonstrated that the active X chromosome was translocated (X-autosome: X; 14).

To assess whether this was a de novo or a segregating chromosomal abnormality, we studied the karyotype of both parents. Their karyotypes were normal, implying that the chromosomal abnormality was de novo. Furthermore, our patient did not present clinical manifestations associated with X-linked recessive diseases.

**Discussion**

X-autosome translocations are extremely rare (one in 30,000). In women, one of the X chromosomes is inactive, and this inactivation is completely random. This phenomenon is called lyonization. In cases of X-autosome translocation, the inactivation is not random but involves the none-translocated X chromosome [9,10].

We must consider that the X-inactivation center in the Xq13 area is turned off in the translocated chromosome, and different genes, which are important for the development and/or the functionality of the ovary, are present on the long arm of chromosome X [11]. We can assume that X-autosome translocations do not interrupt the genes involved in ovarian functionality, but that they cause altered expression, because of their ‘position effect’ [12].

In females with an active X chromosome translocated in all cells and with the breakpoint not interrupting any functional gene, about half have ovarian failure (breakpoints within the Xq13 to q26 region) and the other half have a normal phenotype (breakpoints outside the Xq13 to q26 region) [13-15].

**Conclusions**

The purpose of this therapy was not only to intervene in her climacteric symptoms, but to realize at the same time primary and/or secondary prevention of osteoporosis, cardiovascular pathology and cerebral involutorial pathologies.

### Table 1 Hormonal assays

| Hormonal evaluation                | Result | Normal range |
|-----------------------------------|--------|--------------|
| Thyroid-stimulating hormone (mIU/mL) | 3.01   | 0.40 to 4.50 |
| Free tri-iodothyronine (pg/mL)    | 4.21   | 2.30 to 5.10 |
| Free thyroxin (ng/dL)             | 1.32   | 0.80 to 2.00 |
| Thyroglobulin (ng/mL)             | 3.2a   | <25          |
| Anti-thyroid peroxidase antibodies (IU/mL) | 172a   | <30          |
| Anti-thyroglobulin antibodies (IU/mL) | 488a   | <50          |
| Parathyroid hormone (ng/mL)       | 32.42  | 9 to 72      |
| Follicle-stimulating hormone (IU/L) | 79.90a | <30          |
| Luteinizing hormone (IU/L)        | 41.17a | <9           |
| 17-beta-estradiol (pg/mL)         | 9      | <10          |
| Prolactin (ng/mL)                 | 6.2    | <20          |
| Testosterone (ng/mL)              | 0.22   | 0.1 to 1.0   |
| Testosterone-free (pg/mL)         | 1.4    | 1.1 to 3.1   |

*aOutside of normal range.*
Figure 1 Karyotype 46, X, t(X; 14)(q13;p12).
Our study has underlined that karyotyping is one of the fundamental investigations in the evaluation of amenorrhea. It has highlighted a genetic etiology for amenorrhea in the form of a chromosomal abnormality.

Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DD analyzed and interpreted the patient data and wrote the manuscript. AT, EM, GNM, AM and EP worked up the clinical details and helped to prepare the manuscript. AAE, DL and ML studied the androgen receptor gene. OC and MR performed the fluorescent in situ hybridization. All authors read and approved the final manuscript.

Author details
1Unit of Cytogenetic and Molecular Genetics, Madonna delle Grazie Hospital, Matera 75100, Italy. 2Obstetrics and Gynecology Department, V. Fazzi Hospital, Lecce, Italy. 3Department of Biology, University of Bari, Bari, Italy. 4Unit of Clinical Chemistry, Madonna delle Grazie Hospital, Matera, Italy. 5Obstetrics and Gynecology Department, Santa Maria Hospital, Bari, Italy. 6Department of Ophthalmology, Sapienza University, Rome, Italy. 7S’Andrea Hospital, Sapienza University, Rome, Italy.

Received: 5 June 2012 Accepted: 20 September 2012 Published: 29 October 2012

References
1. Nelson LM: Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009, 360:6106–614.
2. Massin N, Meduri G, Bachelot A, Misrahi M, Kuttenn F, Touraine P: Evaluation of different markers of the ovarian reserve in patients presenting with premature ovarian failure. Mol Cell Endocrinol 2008, 282:1-2:95–100.
3. Massin N, Czernichow C, Thibaud E, Kuttenn F, Polak M, Touraine P: Idiopathic premature ovarian failure in 63 young women. Horm Res 2006, 65(2):89–95.
4. Attomäki K, Lucena JL, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kakkani R, Sankila EM, Lehväslaiho H, Engel AR, Nieschlag E, Huhtaniemi I, de la Chapelle A: Mutation in the follicle-stimulating hormone receptor

Table 2 BAC clones used for fluorescent in situ hybridization with its location on the X chromosome

| Clone     | Band | Position          | FISH resolution |
|-----------|------|------------------|-----------------|
| RP11-450P7 | Xp11.1 | chrX:21,533,785-21,657,970 | derX           |
| RP11-21E13 | Xp11.1 | chrX:57,294,374-57,500,705 | derX           |
| RP11-63004 | Xq13.3 | chrX:73,819,700-73,985,772 | derX           |
| RP11-91J20 | Xq13.3 | chrX:74,412,682-74,572,432 | derX           |
| RP11-194N18 | Xq13.3 | chrX:75,606,737-75,754,256 | der14          |
| RP11-28L16 | Xq21.1 | chrX:76,249,350-76,405,210 | der14          |
| RP11-19G6  | Xq21.1 | chrX:77,789,620-77,954,427 | der14          |
| RP11-91G23 | Xq21.1 | chrX:79,149,705-79,309,977 | der14          |
| RP11-336F4 | Xq21.1 | chrX:83,463,633-83,463,726 | der14          |
| RP11-210I11 | Xq21.1 | chrX:90,459,260-90,599,859 | der14          |
| RP11-138B3 | Xq22.1 | chrX:98,535,557-98,698,689 | der14          |
| RP11-265K3 | Xq28  | chrX:154,603,527-154,763,828 | der14          |

Table 2 BAC clones used for fluorescent in situ hybridization with its location on the X chromosome.

The clones can be displayed on the site of the University of California, Santa Cruz [8]. FISH: fluorescent in situ hybridization.
gene causes hereditary hypergonadotropic ovarian failure. Cell 1995, 82(6):959–968.

5. Dragojević-Dikić S, Marisavljević D, Mitrović A, Dikić S, Jovanović T, Janković-Raznatović S: An immunological insight into premature ovarian failure (POF), Autoimmun Rev 2010, 9(11):771–774.

6. Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, Al-Inany HG, Falcone T: Gonadotropin-releasing hormone analog co-treatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011, 95(3):906–914.

7. Vujović S: Aetiology of premature ovarian failure. Menopause Int 2009, 15(2):72–75.

8. Human (Homo sapiens) Genome Browser Gateway. http://genome.ucsc.edu/cgi-bin/hgGateway?db=hg18.

9. Cottrell CE, Sommer A, Wenger GD, Bullard S, Busch T, Nash Krahm K, Lidral AC, Gastier-Foster JM: Atypical X-chromosome inactivation in an X;1 translocation patient demonstrating Xq28 functional disomy. Am J Med Genet A 2009, 149A(3):408–414.

10. Schmidt M, Du Sart D: Functional disomies of the X chromosome influence the cell selection and hence the X inactivation pattern in females with balanced X-autosome translocations: a review of 122 cases. Am J Hum Genet 1992, 42(2):161–169.

11. Wolff DJ, Schwartz S, Carrel L: Molecular determination of X inactivation pattern correlates with phenotype in women with a structurally abnormal X chromosome. Genet Med 2000, 2(2):36–141.

12. Baronechelli S, Villa N, Redaelli S, Lission S, Saccheri F, Panzeri E, Conconi D, Bentivenga A, Crosti F, Sala E, Bentola F, Marozzi A, Pecotini A, Venturo M, Police MA, Dalprà L: Investigating the role of X chromosome breakpoints in premature ovarian failure. Mol Cytogenet 2012, 5(1):32.

13. Layman L: Human gene mutations causing infertility. J Med Genet 2002, 42(1):36–141.

14. Rizzolio F, Sala C, Alboresi S, Biondi S, Gilli S, Goergen M, Pramparo T, Zuffardi O, Toniolo D: Epigenetic control of the critical region for premature ovarian failure on autosomal genes translocated to the X chromosome: a hypothesis. Hum Genet 2007, 121(3-4):441–450.

15. Schlessinger D, Herrera L, Crisponi L, Mummm S, Percucepe A, Pellegrini M, Pilà G, Forabosco A: Genes and translocations involved in POF. Am J Med Genet 2002, 111(3):328–333.

doi:10.1186/1752-1947-6-368

Cite this article as: Dell’Edera et al.: Clinical correlation between premature ovarian failure and a chromosomal anomaly in a 22-year-old Caucasian woman: a case report. Journal of Medical Case Reports 2012, 6:368.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit